pharmaphorum

MARCH 10, 2022

Tapping into the momentum of biologics requires investment but identifying the right areas to invest in is a challenge in an evolving market. However, producing generic treatments is significantly different to developing synthesised small-molecule drugs, pushing companies like Chiesi to re-evaluate their role in drug production.

Production 97

Production Life Science Development Gene Therapy 97

pharmaphorum

JUNE 20, 2022

“We have a lot of data about pharmaceutical pipelines, sales in the market, and, crucially, about the forecasts and how the market might evolve, which is all derived from sell-side equity analysts,” Verdin states. If you have a pipeline, you hope to see a return, and there are patients at the end of this who do see a benefit.”

Drugs 52

Drugs Marketing Life Science Regulation 52

Drug Discovery World

FEBRUARY 23, 2023

Instead of being limited to the infinitely tiny fraction of possible proteins that nature has evolved over 3.5 This is a direction that several organisations, including Generate Biomedicines, are now exploring. What are the roots of this new direction in protein therapeutics? Two main characteristics differentiate.

Protein 52

Protein Life Science Bioassay Development 52

The Pharma Data

MARCH 16, 2021

Viruses naturally evolve over time. We have developed a growing number of diagnostic solutions that help to detect and diagnose the infection in patients, as well as providing digital support to healthcare systems, and we continue to identify, develop and support potential therapies which can play a role in treating the disease.

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

pharmaphorum

FEBRUARY 1, 2022

With limited physical access to labs and patients, the influx of updated technology was a welcome change. This is hardly surprising, given that the NHS in the UK is one of the few organisations still using fax machines and pagers to conduct daily activities. this is not always a straightforward process.

Life Science 52

Life Science 52

The Pharma Data

MARCH 22, 2021

Basel, 23 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients (n=4,567; REGN-COV 2067). Key results from phase III REGN-COV 2067 trial in non-hospitalised patients 1-3. Patients with ?

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

JULY 23, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 52

Antibody Medicine Production In-Vitro 52

Drug Discovery World

MAY 11, 2023

According to the panellists, companies must adopt new processes, focus on speed and simplification, embrace digitisation, stay open to new and varied collaborations, and ensure patient centricity remains the reason we’re all doing what we’re doing.

Life Science 52

Life Science Genetics Vaccination Vaccine 52

The Pharma Data

JUNE 26, 2021

The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. “This new test, the twelfth in the Roche SARS-CoV-2 testing portfolio, is another essential addition to support healthcare systems and patients as we jointly fight COVID-19.”.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

pharmaphorum

MAY 18, 2022

Health data research in the UK is rapidly evolving, with new capabilities emerging through the rise of hybrid engagement and the accelerated adoption of digital technologies. However, expanding that model to cover all data in all disease areas is a monumental and highly ambitious task.

Research 78

Research Clinical Research Trials Pharma Companies 78

pharmaphorum

OCTOBER 6, 2020

But for many life sciences organisations, these tools are either not yet fully adopted or are not being put to good use within their regulatory functions. Adopting intelligent automation could help organisations realise disruptive benefits that are above and beyond the tangible gains of cost, quality and productivity improvements.

Regulation 103

Regulation Life Science Production HR 103

pharmaphorum

SEPTEMBER 2, 2022

The healthcare industry is evolving rapidly, with data and digital technologies transforming everyday communications as we know them. This disruption has changed the way doctors and cancer patients expect to experience services and products, and there is no going back now. The digital age is here to stay. About the author.

Doctors 59

Doctors Doctor Production Development 59

pharmaphorum

MAY 24, 2021

The marketing content mix for pharma is evolving and pharma marketers are eager to find ways to produce more content, quickly, while reducing inefficiencies and generating savings,” explains Robb. It can be used for sales, marketing and patient communication materials, in print or digital form.

Marketing 89

Marketing Branding Sales Life Science 89

Drug Discovery World

FEBRUARY 5, 2024

This strategic approach could enable significant cost savings in the broader drug development procedure, and importantly, expedite the delivery of more drugs to patients who need them most. AI continues to evolve of course, too, adding to the possibilities. Here, the meta model queries to deliver the answer.)

Life Science 59

Life Science Drugs Marketing Clinical Trials 59

Drug Discovery World

FEBRUARY 15, 2023

However, over the last few decades, it has been widely accepted that interaction between the tumour and host immune response plays a critical role in regulating tumour biology and hence its progression. Patient-derived xenograft (PDX) models 9 are widely used for oncology and immuno-oncology research.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

SEPTEMBER 3, 2020

As COVID-19 and influenza infections can hardly be differentiated based on symptoms, healthcare professionals can confidently provide the right diagnosis and best course of treatment for patients. Negative results must be combined with clinical observations, patient history and epidemiological information.

In-Vitro 40

In-Vitro Antibody Medicine Clinical Trials 40

pharmaphorum

JUNE 14, 2022

The investment flowing into the sector is not limited to just the development of medicines, there has also been a focus on rapidly developing capability and capacity to manufacture both traditional pharmaceuticals and biologic medicines. Evolving regulatory landscape.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

Pharmaceutical Technology

JUNE 20, 2023

The current tech landscape is rapidly evolving, with advancements in areas such as big data and conversational platforms. Consent documents often describe technical medical conditions and regulatory bodies are increasing pressure on sponsors to ensure that patient-facing information can be easily understood by patients.

Life Science 130

Life Science Clinical Trials Clinical Trials Regulation 130

Pharmaceutical Technology

FEBRUARY 20, 2023

He says these issues must be urgently addressed over the next few years as advancing medical knowledge and the role of genomics in treating disease ushers in a new era of precision medicine and new potential to address diseases that affect certain populations. Can you tell us a little bit about Viroclinics-DDL?

Research 130

Research Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

MAY 9, 2023

The clinical trials landscape is evolving more rapidly than ever before. The Covid-19 pandemic catalysed an enormous upswing in the adoption of innovations including telemedicine, wearables and remote patient monitoring. The COVID-19 pandemic and geopolitical instability have put new pressures on the pharmaceutical supply chain.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130